Azitra, Inc. to Present at BIO Investment & Growth Summit
Rhea-AI Summary
Azitra (NYSE American: AZTR) will present at the BIO Investment & Growth Summit in Miami Beach on March 2-3, 2026, with a formal presentation on March 2 at 2:15 PM ET.
Management will highlight pipeline updates for ATR-12 (Phase 1b), ATR-04 (Phase 1/2) and ATR-01 (IND-enabling), and hold one-on-one investor meetings.
Positive
- None.
Negative
- None.
News Market Reaction – AZTR
In the Feb 19 session, AZTR gained 7.23%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.1% during that session. Argus tracked a trough of -6.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 06 | Special meeting adjourned | Negative | -0.7% | Adjourned special meeting after failing to reach quorum on dilutive warrant vote. |
| Jan 07 | Investor conference | Positive | +6.8% | Biotech Showcase presentation and 1:1 meetings highlighting strategy and milestones. |
| Dec 17 | Listing plan accepted | Positive | -1.3% | NYSE American accepted listing compliance plan with deadline of Apr 1, 2027. |
| Nov 24 | Private placement | Positive | +2.9% | Priced $1.5M private placement with shares and warrants at $0.32. |
| Nov 12 | Earnings & updates | Positive | +2.0% | Q3 2025 results plus ATR-04 first dosing and positive ATR-01 preclinical data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news—covering conferences, financings, compliance, and governance—has typically produced modest moves, with the stock reacting directionally in line with news tone in most cases.
Over the last few months, Azitra has balanced capital-raising and listing compliance efforts with ongoing clinical and investor outreach. A Q3 2025 update highlighted first dosing in the ATR-04 Phase 1/2 trial and positive ATR-01 preclinical data. A $1.5M private placement in Nov 2025, subsequent NYSE American compliance plan acceptance, and proxy-driven governance steps around additional share issuance all framed financing and listing risk. Multiple investor conference presentations, including Biotech Showcase and now the BIO Investment & Growth Summit, emphasize the same ATR-12, ATR-04, and ATR-01 pipeline story.
Key Terms
phase 1b medical
phase 1/2 medical
ind-enabling studies regulatory
fast track designation regulatory
fda regulatory
live biotherapeutic products medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome; ATR-04, being developed in a Phase 1/2 trial for the treatment of moderate to severe EGFRi-associated dermal toxicity in adults; and ATR-01 targeting ichthyosis vulgaris, which is undergoing IND-enabling studies.
Details are as follows:
Event: | BIO Investment & Growth Summit |
Date & Time: | Monday, March 2, 2026, 2:15 PM ET |
Location: | Ballroom 2C, Eden Roc Miami Beach Hotel |
Presenter: | Travis Whitfill, Chief Operating Officer |
Registration: |
During the events, members of Azitra's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the Company's clinical development strategy, recent corporate achievements, and anticipated milestones.
About Azitra
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of (i) our results for the Phase 1b clinical trial for our ATR-12, (ii) the development for the Phase 1/2 clinical trial for our ATR-04 program and the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and (iii) statements about our clinical and preclinical programs, including ATR-01, and corporate and clinical/preclinical strategies.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the timing of clinical trials and their results as we may experience delays in the provision of results for ATR-12 or, if we do, that such data may not be favorably received; the safety and efficacy of our product candidates; possible delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the United States Securities and Exchange Commission on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-to-present-at-bio-investment--growth-summit-302692104.html
SOURCE Azitra, Inc.